An interventional study to access the effect of Homoeopathic medicine in positive cases of COVID-19.
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2020/07/026757
- Lead Sponsor
- Ministry of AYUSH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Subjects testing positive for SARS CoV-2 by RT-PCR, presenting with no symptoms or mild symptoms.
2. Subjects who are ready to provide written/digital informed consent and who are willing to participate and follow the protocol requirements of the clinical study.
1. Cases of COVID-19 with clinical severity ranging from moderate to critical.
2. Pregnant and lactating females.
3. Subjects having uncontrolled and unstable co morbidity.
4. Immunocompromised subjects or those taking any kind of immunosupressive therapy.
5. COVIC-19 positive cases participating as subjects in other COVID-19 clinical trails.
6. Subjects having past history of allergy to any medicine that is part of the Homoeopathic intervention. Other conditions, which in the opinion of the investigator, makes the patient unsuitable for enrollment or could interfere with his participation in, and completion of the protocol.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the effectiveness of Homoeopathic medicine Eupatorium perfoliatum 30 C in preventing the progression of severity of the disease in the SARS-Cov-2 tested positive asymptomatic and mild cases of COVID-19.Timepoint: 3 month
- Secondary Outcome Measures
Name Time Method 1. To assess the changes in Quality of Life (QoL) of the subjects using WHO QOL-BREF scale. <br/ ><br>2. To assess the safety of Eupatorium perfoliatum 30 C drug by observing for adverse events.Timepoint: 3 months